Literature DB >> 11305115

Pharmacologic inhibitors of MKK1 and MKK2.

N G Ahn1, T S Nahreini, N S Tolwinski, K A Resing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11305115     DOI： 10.1016/s0076-6879(01)32219-x

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  18 in total

1.  Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Authors:  John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2010-10-05       Impact factor: 6.261

2.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.

Authors:  Joyce Liu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

4.  Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.

Authors:  A von Gise; P Lorenz; C Wellbrock; B Hemmings; F Berberich-Siebelt; U R Rapp; J Troppmair
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 5.  Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.

Authors:  Jeremy L Yap; Shilpa Worlikar; Alexander D MacKerell; Paul Shapiro; Steven Fletcher
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

6.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

8.  Connexin hemichannels and gap junction channels are differentially influenced by lipopolysaccharide and basic fibroblast growth factor.

Authors:  Elke De Vuyst; Elke Decrock; Marijke De Bock; Hiroshi Yamasaki; Christian C Naus; W Howard Evans; Luc Leybaert
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

Review 9.  MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

Authors:  Pui-Kei Wu; Jong-In Park
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

10.  Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma.

Authors:  Yuri Kim
Journal:  Nutr Res Pract       Date:  2010-08-31       Impact factor: 1.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.